KindlyMD (NASDAQ:NAKA) CEO Acquires $309,746.30 in Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey purchased 55,115 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was bought at an average cost of $5.62 per share, with a total value of $309,746.30. Following the acquisition, the chief executive officer owned 3,175,476 shares in the company, valued at $17,846,175.12. This represents a 1.77% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

KindlyMD Price Performance

NASDAQ NAKA traded up $0.20 on Thursday, hitting $5.60. The company had a trading volume of 1,023,533 shares, compared to its average volume of 228,370. The company’s fifty day moving average price is $8.21 and its 200-day moving average price is $13.07. KindlyMD, Inc. has a 12-month low of $4.50 and a 12-month high of $995.60.

KindlyMD (NASDAQ:NAKA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($15.20) EPS for the quarter. The company had revenue of $2.68 million during the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%. As a group, research analysts predict that KindlyMD, Inc. will post -16.8 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on NAKA. Wall Street Zen upgraded shares of KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. TD Cowen began coverage on shares of KindlyMD in a research report on Friday, April 10th. They issued a “buy” rating and a $40.00 target price for the company. Maxim Group reduced their target price on shares of KindlyMD from $60.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, April 6th. B. Riley Financial reduced their target price on shares of KindlyMD from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, February 23rd. Finally, Weiss Ratings upgraded shares of KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $30.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Sagespring Wealth Partners LLC purchased a new position in KindlyMD during the fourth quarter worth about $28,000. SG Americas Securities LLC purchased a new position in KindlyMD during the fourth quarter worth about $61,000. Virtu Financial LLC purchased a new position in KindlyMD during the fourth quarter worth about $151,000. J. Derek Lewis & Associates Inc. purchased a new position in KindlyMD during the fourth quarter worth about $167,000. Finally, Truist Financial Corp purchased a new position in KindlyMD during the fourth quarter worth about $176,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.